{"id":390115,"date":"2021-01-20T00:00:00","date_gmt":"2021-01-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0056-2021-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-without-diarrhea\/"},"modified":"2026-03-31T10:43:58","modified_gmt":"2026-03-31T10:43:58","slug":"algoim0056-2021-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-without-diarrhea","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0056-2021-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-without-diarrhea\/","title":{"rendered":"Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS Without Diarrhea (Including IBS-Constipation) | US | 2021"},"content":{"rendered":"<p>Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes, constipation predominant, diarrhea predominant, and mixed; however, prior to 2017, only two\u00a0ICD-10\u00a0codes existed:\u00a0IBS\u00a0with diarrhea and\u00a0IBS\u00a0without diarrhea. For the purposes of this analysis, we focus on the\u00a0IBS\u00a0without diarrhea population, which includes\u00a0IBS-constipation (IBS-C). Limited treatment options are available for\u00a0IBS, and only a few drugs have secured an\u00a0FDA\u00a0approval for\u00a0IBS-C. Current treatment options include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), guanylate cyclase-C agonists (Allergan\u2019s Linzess and Synergy Pharmaceuticals\u2019 Trulance), and bicyclic fatty acids (Takeda\u2019s Amitiza), all of which are only moderately effective in treating the disease. QUESTIONS ANSWERED<\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed\u00a0IBS\u00a0without diarrhea (including\u00a0IBS-C)patients? What are the quarterly trends in prescribing among recently treated and new diagnosed\u00a0IBS\u00a0without diarrhea (including\u00a0IBS-C) patients?<\/li>\n<li>How have Linzess and Trulance been integrated into the treatment algorithm?<\/li>\n<li>What proportion of\u00a0IBS\u00a0without diarrhea (including IBS-C) patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>What percentage of\u00a0IBS\u00a0without diarrhea (including\u00a0IBS-C) patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients with\u00a0IBS\u00a0without diarrhea (including\u00a0IBS-C)?<\/li>\n<li>\u00a0<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION\u00a0<em>Treatment Algorithms: Claims Data Analysis\u00a0<\/em>provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing brand share.<\/p>\n","protected":false},"template":"","class_list":["post-390115","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-irritable-bowel-syndrome","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390115\/revisions"}],"predecessor-version":[{"id":393240,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390115\/revisions\/393240"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}